The short version of mass spectrometry fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-06-03. Anything still debated is marked as such rather than presented as settled.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Typical form for short synthetic peptides |
| Solubility class | Freely soluble in water and aqueous buffer | Dissolution aided by gentle mixing, not vigorous shaking |
| Typical storage temperature | −20 °C, desiccated | −80 °C used for long-term holding |
| Common analytical method | Reverse-phase HPLC with UV detection near 214 nm | Identity confirmed separately by mass spectrometry |
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming varies between suppliers and publications |
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
The French tried to reach Kaluga and swing through southern Russia, where they could find food and forage supplies. In the Battle of Maloyaroslavets, the replenished Russian army blocked the road to Kaluga. While an indecisive engagement, it nevertheless doomed the Grande Armée; with the Russians refusing to be dislodged, Napoleon was forced to retreat back down the Smolensk road along which he had already advanced, and which had already been denuded of supplies—most crucially, food. The French supply chain, already in tatters from the attrition of wagons and horses, began to collapse completely. The lack of horses also rendered Napoleon's cavalry ineffective, leaving the Grande Armée vulnerable to sustained guerrilla warfare by Russian peasants and irregular troops. The Grande Armée was dealt a further catastrophic blow by the onset of the Russian Winter, which the underfed and undersupplied Grande Armée was unprepared to cope with. When the remnants of Napoleon's army struggled across the Berezina River in November with the Russian army in pursuit, only 27,000 fit soldiers survived, with 380,000 men dead or missing and 100,000 captured. Napoleon then left his men and returned to Paris to prepare the defence against the advancing Russians. The campaign had effectively ended on 14 December 1812, when the last enemy troops left Russia. The Russians had lost around 210,000 men, but with their shorter supply lines, they soon replenished their armies. For every six soldiers of the Grande Armée that entered Russia, only one would make it out in fighting condition.
== Identification == Identifying what is and is not a mushroom requires a basic understanding of their macroscopic structure. Most are basidiomycetes and gilled. Their spores, called basidiospores, are produced on the gills and fall in a fine rain of powder from under the caps as a result. At the microscopic level, the basidiospores are shot off basidia and then fall between the gills in the dead air space. As a result, for most mushrooms, if the cap is cut off and placed gill-side-down overnight, a powdery impression reflecting the shape of the gills (or pores, or spines, etc.) is formed (when the fruit body is sporulating). The color of the powdery print, called a spore print, is useful in both classifying and identifying mushrooms. Spore print colors include white (most common), brown, black, purple-brown, pink, yellow, and creamy, but almost never blue, green, or red.
== Current research == New treatments and clinical trials for breast cancer patients, non-small cell lung cancer patients, and patients with high grade gliomas or other solid tumors with leptomeningeal disease are currently being explored. People with leptomeningeal metastasis are generally excluded from clinical trials, thereby limiting the systematic assessment of novel therapies in this subgroup of patients with poor prognosis. More patients with leptomeningeal metastasis should be enrolled into trials investigating novel agents with the potential to penetrate the blood–brain barrier. Novel approaches are being studied as currently available therapies are toxic and provide limited benefits.
Between 1981 and 1987, the relationship between Noriega and the U.S. grew considerably. It was driven both by the U.S.'s pursuit of its security interests, and Noriega using these as an effective means of gaining favor. The emergence of internal conflicts in Nicaragua and El Salvador between 1979 and 1981 led the Reagan administration to look for allies in the region, including in Panama. Noriega acted as a conduit for U.S. support, including funds and weapons, to the Contra rebels in Nicaragua. He allowed the CIA to establish listening posts in Panama, and also helped the U.S.-backed Salvadoran government against the leftist Salvadoran insurgent Farabundo Martí National Liberation Front. U.S. spy ships used bases in Panama in their operations against the Nicaraguan government, and much of the intelligence gathered by these ships was processed in the U.S. bases in Panama. Noriega permitted these activities despite the Panama Canal treaties restricting the use of the U.S. bases to protecting the canal. Bush, now U.S. vice president, met again with Noriega in December 1983 to discuss support for the Contras. Noriega had a working relationship with U.S. Marine Corps Lieutenant Colonel Oliver North by 1985. Noriega offered to assassinate or sabotage Sandinista leaders in return for North helping Noriega improve his image with the U.S. government. In June 1985 North met with Noriega in Panama and Noriega agreed to train Contra soldiers in Panama for an invasion of Nicaragua in 1986. In return for Panama's support for U.S.
== Chemistry == Bromantane is an adamantane derivative. It is also known as adamantylbromphenylamine, from which its name was derived. Closely related adamantanes with similar effects include adapromine, amantadine, chlodantane, gludantane (gludantan), memantine, and rimantadine.
Sources: en.wikipedia.org
=== Toxicology data === In the 1990s, fialuridine (FIAU) was investigated in clinical trials. The first trial was a 10-day trial in which 43 patients, who were infected with HIV and hepatitis B, demonstrated effective antiviral activity. A subsequent second dose-ranging study was done on 24 patients with hepatitis B over a period of four weeks. The second trial showed significant viral suppression at intermediate doses. However, patients later relapsed, meaning that the viral infection had returned. A longer, 6-month NIH-sponsored, third trial was planned to be conducted, but severe toxicity emerged at patients who had participated in the second trial. Many severe and fatal adverse effects were reported, including lactic acidosis, acute liver failure, peripheral neuropathy, multiple organ failure, and mitochondrial toxicity. A 60-year-old patient died from liver failure and lactic acidosis four months after the second trial. During the third trial, many patients experienced unpleasant side effects such as nausea and vomiting to such an extent that the researchers decided to end the trial. A theory put forward by Dr. Yung-Chi Chang of Yale University in 1991, which hypothesize that FIAU damaged the mitochondrial DNA, thereby giving rise to delayed toxicity. Urgent attempts were subsequently made to counteract the loss of mitochondria. However, by July 16, three patients had died, of whom two had already received a liver transplant and one was waiting for one. By August 1993, two more patients reported to be gravely ill and two other patients had also died.
=== Naming === In Mendeleev's nomenclature for unnamed and undiscovered elements, meitnerium would be called eka-iridium. In 1979, during the Transfermium Wars (but before the synthesis of meitnerium), IUPAC published recommendations per which the element was to be called unnilennium (symbol Une), a systematic element name as a placeholder, until the element is discovered (and the discovery then confirmed) and a permanent name is decided on. Though widely used in the chemical community on all levels, from chemistry classrooms to advanced textbooks, the recommendations were mostly ignored among scientists in the field, who either called it "element 109", with the symbol E109, (109) or even simply 109, or used the proposed name "meitnerium". The naming of meitnerium was discussed in the Transfermium Wars regarding the names of elements 104–109, but meitnerium was the only proposal and thus was never disputed. The name meitnerium (Mt) was suggested by the GSI team in September 1992 in honor of Austrian physicist Lise Meitner, a co-discoverer of protactinium (with Otto Hahn), and one of the discoverers of nuclear fission. In 1994 the name was recommended by IUPAC, and was officially adopted in 1997. It is thus the only element named solely after a non-mythical woman (curium is named for both Pierre and Marie Curie).
== Advantages == The nasal cavity is covered by a thin mucosa which is well vascularised. Therefore, a drug molecule can be transferred quickly across the single epithelial cell layer directly to the systemic blood circulation without first-pass hepatic and intestinal metabolism. The effect is often reached within 5 minutes for smaller drug molecules. Nasal administration can therefore be used as an alternative to oral administration, by crushing or grinding tablets or capsules and snorting or sniffing the resulting powder, providing a rapid onset of effects if a fast effect is desired or if the drug is extensively degraded in the gut or liver. Large-molecule drugs can also be delivered directly to the brain by the intranasal route, the only practical means of doing so, following the olfactory and trigeminal nerves (see section below), for widespread central distribution throughout the central nervous system with little exposure to the blood. This delivery method to the brain was functionally demonstrated in humans in 2006, using insulin, a large peptide hormone that acts as a nerve growth factor in the brain.
The largest and most famous sphinx is the Great Sphinx of Giza, situated on the Giza Plateau adjacent to the Great Pyramids of Giza on the west bank of the Nile River and facing east (29°58′31″N 31°08′15″E). The sphinx is located southeast of the pyramids. While the date of its construction is not known for certain, the consensus among Egyptologists is that the head of the Great Sphinx bears the likeness of the pharaoh Khafre, dating it to between 2600 and 2500 BC. However, a fringe minority of late 20th century geologists have claimed evidence of water erosion in and around the Sphinx enclosure which would prove that the Sphinx predates Khafre, at around 10,000 to 5000 BC, a claim that is sometimes referred to as the Sphinx water erosion hypothesis but which has little support among Egyptologists and contradicts other evidence. What names their builders gave to these statues is unknown. At the Great Sphinx site, a 1400 BC inscription on a stele belonging to the 18th dynasty pharaoh Thutmose IV lists the names of three aspects of the local sun deity of that period, Khepera–Rê–Atum. Many pharaohs had their heads carved atop the guardian statues for their tombs to show their close relationship with the powerful solar deity Sekhmet, a lioness. Besides the Great Sphinx, other famous Egyptian sphinxes include one bearing the head of the pharaoh Hatshepsut, with her likeness carved in granite, which is now in the Metropolitan Museum of Art in New York, and the alabaster Sphinx of Memphis, currently located within the open-air museum at that site.
=== Brown fat cells === Brown fat cells are polyhedral in shape. Brown fat is derived from dermatomyocyte cells. Unlike white fat cells, these cells have considerable cytoplasm, with several lipid droplets scattered throughout, and are known as multilocular cells. The nucleus is round and, although eccentrically located, it is not in the periphery of the cell. The brown color comes from the large quantity of mitochondria. Brown fat, also known as "baby fat," is used to generate heat.
Sources: en.wikipedia.org
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.
Not necessarily. Some vendors use the name for the full 43-residue protein, while others apply it to a short actin-binding fragment or to a related tetrapeptide. The sequence should be confirmed from documentation rather than assumed from the label.
No thymosin beta-4 fragment holds marketing approval as a medicine in major jurisdictions. Material offered for sale is typically labelled for laboratory research only.
The dry powder is normally kept at -20 °C, protected from light and moisture. Reconstituted solutions are often divided into aliquots and stored at -80 °C to reduce freeze-thaw damage.